Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)

Sandostatin LAR (long-acting octreotide acetate) is covered for FDA-indicated uses including acromegaly (to reduce GH and IGF-1), suppression of severe diarrhea and flushing from carcinoid syndrome, long-term management of VIP-tumor–associated watery diarrhea, and for chemotherapy-induced diarrhea when oral antidiarrheals fail. Coverage of the long-acting formulation requires prior trial and documented response/tolerability to short-acting subcutaneous octreotide, intragluteal administration under direct physician supervision, and use consistent with FDA labeling; the short-acting self-administered form is not covered by this A/B MAC.

"Long-acting octreotide acetate (Sandostatin LAR) is covered for reduction of growth hormone (GH) and IGF-1 in patients with acromegaly who are appropriate for medical treatment and who have demonst..."

Sign up to see full coverage criteria, indications, and limitations.